ARTICLE | Cover Story
Making the most of the host
May 12, 2011 7:00 AM UTC
Although recent attention in the HCV space has focused on positive FDA panel recommendations for the protease inhibitors telaprevir and Victrelis
boceprevir from Vertex Pharmaceuticals Inc. and Merck & Co. Inc., respectively,1 a French-led academic group has now uncovered targets on host cells that could also be inhibited to impede HCV entry.2...